Evidence map›Paper›PMID 30055400›Full record

ArticleBiomaterials2018

Enhanced cancer therapy with cold-controlled drug release and photothermal warming enabled by one nanoplatform.

Hai Wang, Pranay Agarwal, Yutong Liang, Jiangsheng Xu, Gang Zhao, Katherine H R Tkaczuk, Xiongbin Lu, Xiaoming He

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. Externally triggered drug delivery systems.Smart materials in medicine · 2024
    Article
  4. Article
  5. Nanoparticles in Cancer Diagnosis and Treatment.Materials (Basel, Switzerland) · 2023
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Hai WangFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA; Department of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Pranay AgarwalDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA.
Yutong LiangFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Jiangsheng XuFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA; Department of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Gang ZhaoCenter for Biomedical Engineering, Department of Electronic Science and Technology, University of Science and Technology of China, Hefei, Anhui 230027, China.
Katherine H R TkaczukMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD 21201, USA.
Xiongbin LuDepartment of Medical and Molecular Genetics and Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Xiaoming HeFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA; Department of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD 21201, USA; Robert E. Fischell Institute for Biomedical Devices, University of Maryland, College Park, MD, 20742, USA. Electronic address: shawnhe@umd.edu.
The Ohio State University · USUniversity of Maryland, Baltimore · USUniversity of Maryland, College Park · USIndiana University Health · USUniversity of Science and Technology of China · CN

Funding

Nanotechnology enabled targeting of p53 deficiency in human cancerR01CA206366 · NCI · UNIV OF MARYLAND, COLLEGE PARK · PI HE, XIAOMING, LU, XIONGBIN · 2016 to 2020
$1.9M
NCI NIH HHS R01 CA206366
6 · The paper itself

Abstract

Stimuli-responsive nanoparticles hold great promise for drug delivery to improve the safety and efficacy of cancer therapy. One of the most investigated stimuli-responsive strategies is to induce drug release by heating with laser, ultrasound, or electromagnetic field. More recently, cryosurgery (also called cryotherapy and cryoablation), destruction of diseased tissues by first cooling/freezing and then warming back, has been used to treat various diseases including cancer in the clinic. Here we developed a cold-responsive nanoparticle for controlled drug release as a result of the irreversible disassembly of the nanoparticle when cooled to below ∼10 °C. Furthermore, this nanoparticle can be used to generate localized heating under near infrared (NIR) laser irradiation, which can facilitate the warming process after cooling/freezing during cryosurgery. Indeed, the combination of this cold-responsive nanoparticle with ice cooling and NIR laser irradiation can greatly augment cancer destruction both in vitro and in vivo with no evident systemic toxicity.

Indexed as

Cell Line, TumorDelayed-Action PreparationsDoxorubicinDrug Delivery SystemsDrug LiberationHumansHyperthermia, InducedNanoparticlesDelayed-Action PreparationsDoxorubicinCold-responsiveCombination therapyNIPAMPhotothermalPLGA

Identifiers

PMID30055400
PMCPMC6174693
OpenAlexW2883012042

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.